In December 2024, we received approval to initiate our Phase 1b clinical trial of GT-02287 in people with GBA1 or idiopathic ...
Gain Therapeutics (GANX) provided a letter to shareholders from the Company’s President and CEO, Gene Mack, which read in part,”With 2025 ...
Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the ...
AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment strategies.
Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and ...
Idiopathic normal pressure hydrocephalus ... vestibular diseases and Parkinson's disease. The differentiation between INPH and Parkinson's disease can be challenging. Both diseases share a ...
AD: Autonomic dysfunction; DaT: Dopamine transporter; MIBG: Metaiodobenzylguanidine; PD: Parkinson's disease ... to diagnose a clinically possible idiopathic PD. A clinically probable PD might ...
Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.
Many regard getting a diagnosis, good or bad, as preferable to living with uncertainty. But if that diagnosis is the wrong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback